US 12,343,405 B2
High sterol-containing lipid nanoparticles
Kevin An, Vancouver (CA); Daniel Kurek, Vancouver (CA); Jayesh Kulkarni, Vancouver (CA); and Dominik Witzigmann, Vancouver (CA)
Assigned to Nano Vation Therapeutics Inc., Vancouver (CA)
Filed by NanoVation Therapeutics Inc., Vancouver (CA)
Filed on Mar. 8, 2024, as Appl. No. 18/599,893.
Application 18/599,893 is a division of application No. 18/187,904, filed on Mar. 22, 2023, granted, now 11,951,177.
Claims priority of provisional application 63/269,815, filed on Mar. 23, 2022.
Prior Publication US 2024/0207439 A1, Jun. 27, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/69 (2017.01); A61K 31/575 (2006.01); A61K 31/661 (2006.01); C12N 15/113 (2010.01)
CPC A61K 47/6909 (2017.08) [A61K 31/575 (2013.01); A61K 31/661 (2013.01); C12N 15/113 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method for delivery of mRNA or vector DNA for in vivo production of protein or peptide in the liver, the method comprising administering to a mammal a lipid nanoparticle having 49 to 85 mol % of a sterol or a derivative thereof, a phospholipid or a phospholipid-sterol conjugate at 0 to 7 mol % that is in a neutral zwitterionic form at physiological pH, an ionizable lipid and a hydrophilic polymer-lipid conjugate present at 0.5 to 1.8 mol %, wherein the mRNA or vector DNA is encapsulated within the lipid nanoparticle and wherein the administering of the lipid nanoparticle results in liver-specific expression of the protein or peptide encoded by the mRNA or vector DNA, wherein the lipid nanoparticle has increased expression of the protein or peptide encoded by the mRNA or vector DNA in the liver over the spleen by at least 20-fold.